CSL vs CSLLY: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: CSL is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CSL and CSLLY share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CSL and CSLLY exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Carlisle Companies Incorporated (NYSE: CSL) is a diversified manufacturer that, after years of portfolio reshaping, has become a focused supplier of building-envelope products that make commercial and residential buildings more energy efficient. It operates through two segments: Carlisle Construction Materials (CCM), which makes single-ply roofing membranes (EPDM rubber, TPO, and PVC), polyiso insulation, and metal roofing and wall systems, and Carlisle Weatherproofing Technologies (CWT), which makes waterproofing, air and vapor barriers, sealants, spray polyurethane foam, coatings, and related moisture-protection products. The company earns most of its revenue from commercial construction, and within that, a large share comes from re-roofing (replacing aging roofs), which is more stable than new construction because roofs wear out on a predictable cycle regardless of the economy.

Full CSL guide

CSL Limited is one of the world's largest biotechnology companies and is listed on the Australian Securities Exchange, with US investors able to hold it through the CSLLY American Depositary Receipt. The group runs three businesses. CSL Behring, the largest at roughly US$11.4 billion of FY26 revenue, collects blood plasma through one of the biggest donor-center networks in the world and fractionates it into therapies such as immunoglobulins (used for immune deficiencies and neurological conditions), albumin, haemophilia treatments and specialty products like the gene therapy HEMGENIX and the hereditary angioedema drug ANDEMBRY. CSL Seqirus, at about US$2.0 billion, is one of the largest influenza vaccine makers globally, with egg-based, cell-based and adjuvanted vaccines and a pandemic-preparedness role for several governments. CSL Vifor, at about US$2.4 billion, sells iron-deficiency and kidney-disease medicines and came with the roughly US$11.7 billion acquisition of Vifor Pharma in 2022. CSL reports in US dollars even though its home listing is in Australian dollars.

Full CSLLY guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• CSL drivers: Commercial re-roofing replacement cycle; Margin expansion and pure-play focus.
• CSLLY drivers: Immunoglobulin recovery at CSL Behring; Plasma cost and margin rebuild.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Carlisle's end markets are cyclical: commercial and residential construction activity is sensitive to interest rates, credit availability, and the broader economy, and a downturn in construction spending would pressure volumes. For CSLLY, the most immediate risk is that immunoglobulin demand stays soft or that competitors such as Grifols, Takeda and Octapharma price aggressively, which would undercut the FY27 guidance the recent rebound is built on.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick CSL if you believe its drivers more; CSLLY if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CSL and CSLLY guides.

CSL. Carlisle now trades near 19x trailing earnings and about 14x forward, below the low-20s multiple it carried earlier in 2026, as the share price has gone roughly sideways while earnings estimates held up. Investors still focus on adjusted EBITDA margin, free cash flow (about $670 million trailing) and the pace of buybacks rather than raw revenue growth, which swings with weather and construction cycles. Third-quarter results arrive October 28, 2026, with consensus near $5.91 in EPS on about $1.42 billion of revenue, and analysts expect about $21.09 of EPS for full-year 2026.

CSLLY. CSL reports in US dollars, which makes its earnings directly comparable to the CSLLY price once the four-ADRs-per-share ratio is applied: one ASX share at about A$185 is roughly US$129, or about US$32 per ADR. At around 20 times underlying earnings, CSL trades well below the 30 to 40 times multiple it commanded for most of the last decade, which reflects both slower expected growth and lower confidence after the guidance cuts. FY26 dividends totalled roughly US$2.92 per share (an interim of about US$1.30 and a final of US$1.62), and the company is continuing an on-market buyback of about US$1.1 billion in FY27. The statutory loss is driven by non-cash impairments and restructuring charges, while operating cash flow held near US$3.5 billion.

Headline figures (approximate, October 2026): CSL shows revenue (ttm) ~$5.1 billion, revenue growth (q2 2026, yoy) ~8%, q2 2026 adjusted eps ~$7.03 vs ~$6.35 consensus, margins (ttm gross / operating / net) ~35% / ~23% / ~14%; CSLLY shows revenue (fy26, year to june 2026) ~US$15.8 billion (down ~1%), underlying npata (fy26) ~US$3.1 billion (down ~2%), statutory result (fy26) ~US$2.6 billion loss after ~US$7.1 billion pre-tax impairments, fy27 guidance ~5% underlying NPAT growth, revenue broadly flat at constant currency.

CSL and CSLLY are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CSL and CSLLY exposure against your real portfolio. It is not an investment adviser.